Financial insights of ATYR

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenues	-	0	190,000	0
Research and development	7,317,000	10,891,000	22,130,000	15,384,000
General and administrative	4,119,000	3,905,000	4,805,000	4,929,000
Total operating expenses	11,436,000	14,796,000	26,935,000	20,313,000
Loss from operations	-11,436,000	-14,796,000	-26,745,000	-20,313,000
Total other income (expense), net	644,000	832,000	999,000	781,000
Consolidated net loss	-10,792,000	-13,964,000	-25,746,000	-19,532,000
Net loss attributable to noncontrolling interest in pangu biopharma limited	-1,000	-1,000	-2,000	-1,000
Net loss attributable to atyr pharma, inc	-10,791,000	-13,963,000	-25,744,000	-19,531,000

Basic EPS	-0.11	-0.142	-0.26	-0.22
Diluted EPS	-0.11	-0.142	-0.26	-0.22
Basic Average Shares	98,043,839	98,182,534	97,153,541	90,120,235
Diluted Average Shares	98,043,839	98,182,534	97,153,541	90,120,235

Unit: Dollar. Numbers labeled with * are estimated quarterly values.